Singular Genomics
OMICPrivate Company
Total funding raised: $449M
Overview
Singular Genomics, founded in 2016, is a public technology platform company focused on revolutionizing spatial biology with its G4X Spatial Sequencing Platform. Its core achievement is developing a system that dramatically increases throughput and integrates multiomic data (RNA, protein, fH&E) to enable large-scale, AI-powered translational studies on clinical tissue archives. The company's strategy is to establish its G4X as the production-scale platform of choice for academic, biopharma, and clinical researchers, thereby driving the discovery of next-generation biomarkers and diagnostics.
Technology Platform
The G4X Spatial Sequencing Platform is a high-throughput, integrated system that performs in situ multiomic sequencing, delivering 500-plex RNA, 18-plex protein, and fH&E histology data from the same FFPE tissue section at subcellular resolution.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Singular competes directly with 10x Genomics (Xenium/Visium) and NanoString (CosMx) in high-plex spatial biology. Its key differentiators are superior integrated throughput (32 sections/run), combined RNA/protein/fH&E data from a single assay, and a sequencing-based chemistry designed for long-term scalability. However, it faces an uphill battle against the dominant market share and commercial resources of 10x.